Open Access<p>Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis</p>
Author(s) -
Masashi Sakayori,
Jiro Terada,
Mitsuhiro Abe,
Yasutaka Hirasawa,
Kenichi Suzuki,
Keiichiro Yoshioka,
Kenji Tsushima,
Koichiro Tatsumi
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s208733
Subject(s) - medicine , tolerability , pirfenidone , discontinuation , adverse effect , idiopathic pulmonary fibrosis , incidence (geometry) , anorexia , gastroenterology , lung , physics , optics
Although pirfenidone (PFD) is a key drug for the treatment of idiopathic pulmonary fibrosis (IPF), differences in tolerability between elderly and young patients remain unclear. This study aimed to investigate age-related differences in adverse drug reactions to PFD and to evaluate whether patient age influences the safety and tolerability of PFD in clinical practice.